NCT02181374

Brief Summary

The purpose of this study is to evaluate the diagnostic value of serum NT - proBNP in stroke associated with nonvalvular atrial fibrilltion.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
1,000

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Jan 2012

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 1, 2012

Completed
2.4 years until next milestone

First Submitted

Initial submission to the registry

June 3, 2014

Completed
1 month until next milestone

First Posted

Study publicly available on registry

July 3, 2014

Completed
2.2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 1, 2016

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

September 1, 2016

Completed
Last Updated

January 1, 2016

Status Verified

December 1, 2015

Enrollment Period

4.7 years

First QC Date

June 3, 2014

Last Update Submit

December 30, 2015

Conditions

Ischemic Stroke

Keywords

atrial fibrillationNT-proBNPCardioembolic Stroke

Outcome Measures

Primary Outcomes (1)

  • The diagnostic value of serum NT - proBNP in stroke associated with nonvalvular atrial fibrilltion

    All included in the cases in 7 days of blood samples , the detection of serum NT - proBNP.Through the single factor analysis to determine the prediction values of serum NT - proBNP in stroke associated with nonvalvular atrial fibrilltion.

    34 months

Eligibility Criteria

Age18 Years - 85 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

18 ≤ Age ≤ 85; meet the clinical diagnostic criteria for acute ischemic stroke; onset within 24 hours at the same time more than one hour; it was diagnosed with experiential doctor.

You may qualify if:

  • ≤ Age ≤ 85;
  • Meet the clinical diagnostic criteria for acute ischemic stroke;
  • onset within 7 days;

You may not qualify if:

  • Severe systemic disease (chronic inflammation, infection, blood system diseases, cancer, kidney failure, liver failure,heart failure);
  • Nearly a month history of myocardial infarction;
  • pregnant;
  • Serious neurological disease that the diagnosis is unclear;

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

The Department of Neurology, Xijing Hospital

Xi'an, Shaanxi, 710032, China

RECRUITING

Biospecimen

Retention: SAMPLES WITHOUT DNA

NT-proBNP

MeSH Terms

Conditions

Ischemic StrokeAtrial FibrillationEmbolic Stroke

Condition Hierarchy (Ancestors)

StrokeCerebrovascular DisordersBrain DiseasesCentral Nervous System DiseasesNervous System DiseasesVascular DiseasesCardiovascular DiseasesArrhythmias, CardiacHeart DiseasesPathologic ProcessesPathological Conditions, Signs and Symptoms

Study Officials

  • Wen Jiang, MD

    The Department of Neurology, Xijing Hospital

    STUDY DIRECTOR

Central Study Contacts

Wen Jiang, MD

CONTACT

02984775361jiangwen@fmmu.edu.cn

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
PROSPECTIVE
Target Duration
5 Years
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

June 3, 2014

First Posted

July 3, 2014

Study Start

January 1, 2012

Primary Completion

September 1, 2016

Study Completion

September 1, 2016

Last Updated

January 1, 2016

Record last verified: 2015-12

Locations

CN(1)